检索范围:
排序: 展示方式:
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian
《医学前沿(英文)》 2019年 第13卷 第1期 页码 32-44 doi: 10.1007/s11684-018-0678-0
Immunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpoint inhibitor treatment, including tumor-specific profiles and tumor microenvironment evaluation and other factors.
关键词: immune checkpoint companion diagnosis PD-L1 tumor mutation burden immune score
662 A/G gene variation in human tumor necrosis factor receptor superfamily, member 9 (TNFRSF9)
QU Yanchun, YANG Ze, SUN Liang, JI Linong
《医学前沿(英文)》 2008年 第2卷 第3期 页码 283-285 doi: 10.1007/s11684-008-0053-7
关键词: D-HPLC mutation development autoimmune PCR-RFLP candidate
Curbing the burden of lung cancer
null
《医学前沿(英文)》 2016年 第10卷 第2期 页码 228-232 doi: 10.1007/s11684-016-0447-x
Lung cancer contributes substantially to the global burden of disease and healthcare costs. New screening modalities using low-dose computerized tomography are promising tools for early detection leading to curative surgery. However, the screening and follow-up diagnostic procedures of these techniques may be costly. Focusing on prevention is an important factor to reduce the burden of screening, treatment, and lung cancer deaths. The International Agency for Research on Cancer has identified several lung carcinogens, which we believe can be considered actionable when developing prevention strategies. To curb the societal burden of lung cancer, healthcare resources need to be focused on early detection and screening and on mitigating exposure(s) of a person to known lung carcinogens, such as active tobacco smoking, household air pollution (HAP), and outdoor air pollution. Evidence has also suggested that these known lung carcinogens may be associated with genetic predispositions, supporting the hypothesis that lung cancers attributed to differing exposures may have developed from unique underlying genetic mechanisms attributed to the exposure of interest. For instance, smoking-attributed lung cancer involves novel genetic markers of risk compared with HAP-attributed lung cancer. Therefore, genetic risk markers may be used in risk stratification to identify subpopulations that are at a higher risk for developing lung cancer attributed to a given exposure. Such targeted prevention strategies suggest that precision prevention strategies may be possible in the future; however, much work is needed to determine whether these strategies will be viable.
The epidemiology of norovirus gastroenteritis in China: disease burden and distribution of genotypes
Honglu Zhou, Songmei Wang, Lorenz von Seidlein, Xuanyi Wang
《医学前沿(英文)》 2020年 第14卷 第1期 页码 1-7 doi: 10.1007/s11684-019-0733-5
关键词: molecular epidemiology norovirus disease burden genotype China
Novel mutation c.1210-3C>G in with a poly-T tract of 5T affects mRNA splicing in a Chinese patient
《医学前沿(英文)》 2022年 第16卷 第1期 页码 150-155 doi: 10.1007/s11684-021-0846-5
Guobin SHAN , Rajeshwar D. TYAGI , Rao Y. SURAMPALLI , Tian C. ZHANG
《环境科学与工程前沿(英文)》 2009年 第3卷 第3期 页码 249-264 doi: 10.1007/s11783-009-0029-0
关键词: nanomaterials industrial agricultural nonpoint source pollution environmental burden reduction
Mutation profiling of 16 candidate genes in
Yang Zhang, Fang Wang, Xue Chen, Wenjing Liu, Jiancheng Fang, Mingyu Wang, Wen Teng, Panxiang Cao, Hongxing Liu
《医学前沿(英文)》 2019年 第13卷 第2期 页码 229-237 doi: 10.1007/s11684-018-0616-1
Heterogeneity of the tumor immune microenvironment and clinical interventions
《医学前沿(英文)》 2023年 第17卷 第4期 页码 617-648 doi: 10.1007/s11684-023-1015-9
Proteins moonlighting in tumor metabolism and epigenetics
Lei Lv, Qunying Lei
《医学前沿(英文)》 2021年 第15卷 第3期 页码 383-403 doi: 10.1007/s11684-020-0818-1
Complex interplay between tumor microenvironment and cancer therapy
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 426-439 doi: 10.1007/s11684-018-0663-7
Tumor microenvironment (TME) is comprised of cellular and non-cellular components that exist within and around the tumor mass. The TME is highly dynamic and its importance in different stages of cancer progression has been well recognized. A growing body of evidence suggests that TME also plays pivotal roles in cancer treatment responses. TME is significantly remodeled upon cancer therapies, and such change either enhances the responses or induces drug resistance. Given the importance of TME in tumor progression and therapy resistance, strategies that remodel TME to improve therapeutic responses are under developing. In this review, we provide an overview of the essential components in TME and the remodeling of TME in response to anti-cancer treatments. We also summarize the strategies that aim to enhance therapeutic efficacy by modulating TME.
关键词: tumor microenvironment therapy response treatment resistance
《医学前沿(英文)》 2023年 第17卷 第4期 页码 699-713 doi: 10.1007/s11684-022-0972-8
关键词: anti-CD19 chimeric antigen receptor T immunotherapy diffuse large B cell lymphoma tumor microenvironment tumor-associated macrophage metabolism
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
null
《医学前沿(英文)》 2012年 第6卷 第1期 页码 67-78 doi: 10.1007/s11684-012-0176-8
Antitumor angiogenic therapy has been shown promising in the treatment of several advanced cancers since the approval of the first antiangiogenic drug Avastin in 2004. Although the current antiangiogenic drugs reduce the density of tumor blood vessels and result in tumor shrinkage at the early stage of treatment, recent studies have shown that antiangiogenic therapy has transient and insufficient efficacy, resulting in tumor recurrence in patients after several months of treatment. Blockage of blood and oxygen supplies creates a hypoxic and acidic microenvironment in the tumor tissues, which fosters tumor cells to become more aggressive and metastatic. In 2001, Jain proposed tumor vascular normalization as an alternative approach to treating cancers based on the pioneering work on tumor blood vessels by several other researchers. At present, normalizing the disorganized tumor vasculature, rather than disrupting or blocking them, has emerged as a new option for anticancer therapy. Preclinical and clinical data have shown that tumor vascular normalization using monoclonal antibodies, proteins, peptides, small molecules, and pericytes resulted in decreased tumor size and reduced metastasis. However, current tumor vascular normalizing drugs display moderate anticancer efficacy. Accumulated data have shown that a variety of vasculogenic/angiogenic tumor cells and genes play important roles in tumor neovascularization, growth, and metastasis. Therefore, multiple-targeting of vasculogenic tumor cells and genes may improve the efficacy of tumor vascular normalization. To this end, the combination of antiangiogenic drugs with tumor vascular normalizing therapeutics, as well as the integration of Western medicine with traditional Chinese medicine, may provide a good opportunity for discovering novel tumor vascular normalizing drugs for an effective anticancer therapy.
关键词: angiogenesis vasculogenesis neovascularization tumor vasculature normalization traditional Chinese medicine
Natural killer cell lines in tumor immunotherapy
null
《医学前沿(英文)》 2012年 第6卷 第1期 页码 56-66 doi: 10.1007/s11684-012-0177-7
Natural killer (NK) cells are considered to be critical players in anticancer immunity. However, cancers are able to develop mechanisms to escape NK cell attack or to induce defective NK cells. Current NK cell-based cancer immunotherapy is aimed at overcoming NK cell paralysis through several potential approaches, including activating autologous NK cells, expanding allogeneic NK cells, usage of stable allogeneic NK cell lines and genetically modifying fresh NK cells or NK cell lines. The stable allogeneic NK cell line approach is more practical for quality-control and large-scale production. Additionally, genetically modifying NK cell lines by increasing their expression of cytokines and engineering chimeric tumor antigen receptors could improve their specificity and cytotoxicity. In this review, NK cells in tumor immunotherapy are discussed, and a list of therapeutic NK cell lines currently undergoing preclinical and clinical trials of several kinds of tumors are reviewed.
关键词: natural killer cell natural killer cell line tumor immunotherapy genetic modification
Kai Shi, Matthew Haynes, Leaf Huang
《化学科学与工程前沿(英文)》 2017年 第11卷 第4期 页码 676-684 doi: 10.1007/s11705-017-1640-4
关键词: vaccine nanoparticle tumor immunotherapy microenvironment
标题 作者 时间 类型 操作
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian
期刊论文
662 A/G gene variation in human tumor necrosis factor receptor superfamily, member 9 (TNFRSF9)
QU Yanchun, YANG Ze, SUN Liang, JI Linong
期刊论文
The epidemiology of norovirus gastroenteritis in China: disease burden and distribution of genotypes
Honglu Zhou, Songmei Wang, Lorenz von Seidlein, Xuanyi Wang
期刊论文
Novel mutation c.1210-3C>G in with a poly-T tract of 5T affects mRNA splicing in a Chinese patient
期刊论文
Nanomaterials for environmental burden reduction, waste treatment, and nonpoint source pollution control
Guobin SHAN , Rajeshwar D. TYAGI , Rao Y. SURAMPALLI , Tian C. ZHANG
期刊论文
Mutation profiling of 16 candidate genes in
Yang Zhang, Fang Wang, Xue Chen, Wenjing Liu, Jiancheng Fang, Mingyu Wang, Wen Teng, Panxiang Cao, Hongxing Liu
期刊论文
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma
期刊论文
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
null
期刊论文